In the only other series that has been similarly analysed Coleman et al (New York) reported that tumour thickness was not a significant predictor of percentage reduction in height. However, they showed that ultrasonically derived spectral parameters did correlate with regression.3 At six months they found that acoustic tissue type (ATT) B had a 29-5% reduction in height, while ATT E had an 11-4% reduction in height. At 18 months ATT B had a 53 9% reduction in height, while ATT E had a 26-4% reduction in height.
Since Stallard's pioneering work scleral radioactive applicators (brachytherapy) has been used in many ways throughout the world. Cobalt-60, iodine-125, iridium-192, and ruthenium-106 have been used. Remarkably little is known about what happens to the ocular tumour in the eye after brachytherapy. Stallard' reported that the majority of melanomas he treated became flat; few other workers have achieved that result. Cruess et al calculated that a 'mean' change in tumour thickness was 20% reduction at six months, 30% at 12 months, and then a progressive decrease of 50% at 54 months. They concluded that the average posterior uveal melanoma treated with cobalt-60 did not regress to a flat scar and that the 'extent and rate of regression' were not reliable indicators of the patient's likelihood of developing metastatic disease.2 In the only other series that has been similarly analysed Coleman et al (New York) reported that tumour thickness was not a significant predictor of percentage reduction in height. However, they showed that ultrasonically derived spectral parameters did correlate with regression.3 At six months they found that acoustic tissue type (ATT) B had a 29-5% reduction in height, while ATT E had an 11-4% reduction in height. At 18 months ATT B had a 53 9% reduction in height, while ATT E had a 26-4% reduction in height.
One ofthe authors of the present paper (DHA) involved in plaque therapy for two patients.
PATTERNS OF CHANGE AND METASTASES
The changes in tumour height over time are plotted in Figure 1 , and see (Fig 2) . In some cases the tumours remained stationary after shrinking and then shrank again. The maximal shrinkage seen was 8-1 mm in 29 months. In cases where the tumour diminished in size after reaching a plateau, the second regression began eight to 60 months after treatment. In these cases the magnitude of change was occasionally dramatic. One patient's tumour shrank 3 100 patients with uveal melanomas treated with cobalt-60 plaques, found that the 'average' posterior uveal melanoma did 'not regress rapidly to a flat, depigmented scar' but 'shrank slowly' to 50% of the thickness of the original tumour after 54 months. In the same paper the authors pointed out that there was no change in the maximal or minimal basal diameter of the tumour during 54 months of follow-up.2 Additional analysis of the same 100 patients revealed that 96% showed a regression and that only three melanomas increased in thickness after therapy. 9 In another analysis of 17 patients from Wills who were followed up for at least three months the post-treatment rate of decrease in tumour thickness (%/month) varied between 1 2 and 10 5. In no patient did the tumour grow after plaque therapy.'0
We found that the mean post-treatment rate of decrease in large tumour thickness was: 2-3%/ month in the first six months, 1-5%/month in the second six months, 0*5%/month in the second year, and 0*9%/month between year 2 and year 4. The changes for medium tumours were 1%, 2%, 0-75%, and 0-45% respectively.
The largest series published in which ultrasonic measurements were made was also from Wills, with an analysis of 159 patients treated between 1976 and 1980. In this series the prognostic value of the regression rate was studied."
Our results generally agree with those ofall the prior studies but have important features not discussed by others. We found that both the absolute and percentage decrease in tumour height were most pronounced in the large tumours and that the decrease in height tends to level off after 30 months. The average monthly decrease in tumour height for the first 48 months was 05 mm for large and 0-2 mm for medium tumours. The mean absolute change in tumour height after treatment in large tumours was 1 8 mm at six months and 5 5 mm at 48 months. For medium sized tumours these means are 0-9 mm and 19 mm respectively. When we actually superimposed each of the individual tumour responses, we could not find two tumours with exactly the same magnitude and time changes (Fig 1) . This emphasises the individual responses of these tumours and should make clinicians wary of any discussion of 'average' changes.
When we looked for trends in height changes, we found that 80 ofthe 82 tumours fell into three categories. The most common (57 out of 82) of these was a progressive decrease in height after treatment (type D). The 
